Patent 11,858,898 US Scope Map and Claim Coverage for Chronic Obstructive Pulmonary Disease Crystalline Freebase (biphenyl-2-ylcarbamic acid piperidinyl ester)
Executive summary: US Drug Patent 11,858,898 is a solid-state and formulation-constrained portfolio with enforceable claim focus on (i) a specific crystalline freebase of a substituted biphenyl-2-ylcarbamic acid 1-(2-{[4-(4-carbamoylpiperidin-1-ylmethyl)benzoyl]methylamino}ethyl)piperidin-4-yl ester, (ii) rigid analytical identifiers (PXRD peak locations and DSC onset), and (iii) downstream CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) treatment via pharmaceutical composition administration, including optional isotonicity, pH 4–6 with citrate buffer at ~pH 5, specified concentration range, and nebulizer delivery. The tightest commercial lockout comes from the PXRD/DSC-defined crystalline freebase identity and the drug product conditions tied to that identity.
What are the exact claim elements in US Patent 11,858,898 (scope of protection for crystalline freebase COPD treatment)?
Core claim coverage: The patent is structured as a “crystal identity + composition + COPD method” scaffold.
Claim 1: Method using a defined crystalline freebase with PXRD signature
Claim 1 covers a COPD method that requires all of the following:
- Disease/indication: treating COPD in a human patient
- Dosage form concept: administering a pharmaceutical composition with a pharmaceutically acceptable carrier and the drug substance being:
- “a crystalline freebase” of the named biphenyl-2-ylcarbamic acid piperidinyl ester
- Solid-state identity constraint:
- powder X-ray diffraction pattern with peaks at 2θ = 6.6 ± 0.1 and 20.2 ± 0.1
- Product delivery is not required in Claim 1 itself (nebulizer appears in dependent claims)
This is a classic chemical-form selection claim. The enforceable boundary is the crystalline form defined by PXRD peak positions, not a broad “any freebase” or “any crystal form.”
Claims 2–3: Additional thermodynamic identity markers (melting and DSC onset)
- Claim 2 adds a melting point constraint: ~125°C
- Claim 3 adds DSC constraint: onset of endothermic heat flow at ~123°C
These do not replace Claim 1’s PXRD. They narrow Claim 1 further when asserted through dependent claims.
Claims 4–7: Formulation attributes and drug concentration
Claims 4–7 add additional composition conditions:
- Claim 4: composition is isotonic
- Claim 5: composition pH about 4–6
- Claim 6: composition buffered with citrate buffer to pH about 5
- Claim 7: composition concentration ~0.05 μg/mL to ~10 mg/mL of the named freebase
Together these dependent claims constrain both physicochemical product design and dose strength window.
Claim 8: Delivery device limitation (nebulizer)
- Claim 8 narrows to COPD treatment where the composition is administered using a nebulizer.
This matters for design-around: an infringing method requires the nebulizer step if only Claim 8 is asserted, but Claim 1 could still be asserted without the nebulizer feature.
How is the crystalline form claimed differently in US 11,858,898 (PXRD peaks 11.4/11.6 vs 6.6/20.2)?
The patent also contains an explicit “crystalline form” definition separate from the crystalline freebase defined by PXRD peaks at 6.6/20.2.
Claim 9: Crystalline form characterized by PXRD peaks at 11.4 and 11.6
Claim 9 recites:
- A crystalline form of the same named compound
- PXRD pattern with peaks at 2θ = 11.4 ± 0.1 and 11.6 ± 0.1
This is a different crystal identifier than Claim 1. It creates a second crystalline-form branch.
Claim 10: DSC onset constraint for Claim 9’s crystalline form
- Claim 10 ties Claim 9 to DSC onset ~123°C.
Claims 11 and 12–13: Composition containing Claim 9/Claim 12 crystalline forms
- Claim 11: pharmaceutical composition with carrier + the crystalline form of Claim 9
- Claim 12–13: restate crystalline form with DSC (Claim 12) and composition (Claim 13)
The patent therefore has parallel lanes:
- “Crystal freebase with PXRD 6.6/20.2” (Claim 1 lane)
- “Crystalline form with PXRD 11.4/11.6” (Claim 9 lane)
The enforcement question becomes whether an accused product uses a crystalline form meeting one of those PXRD-defined sets.
What are the scope overlaps and redundancy patterns across Claims 14–25 (method claims that depend on compositions)?
Claims 14–25 are largely mechanical dependent structures that convert the composition claims into COPD methods.
Claim 14: COPD method using pharmaceutical composition of Claim 11
- COPD treatment by administering the composition of Claim 11 (which is crystalline form from Claim 9 plus carrier)
Claims 15–19: Isotonicity, pH range, citrate buffer, concentration window, nebulizer
- Mirrors Claims 4–8, but now the base composition is defined by Claim 11 rather than Claim 1.
Claims 20–25: COPD method using composition of Claim 13
- COPD treatment by administering the pharmaceutical composition of Claim 13
- Again mirrors isotonicity/pH/buffer/concentration/nebulizer constraints (Claims 21–25)
Practical consequence: There is meaningful coverage for:
- the crystalline form itself (Claims 9/11/12/13)
- the COPD method via administration (Claims 14/20/…)
- incremental formulation/device conditions (15–19, 21–25)
What additional coverage exists for composition preparation in Claims 26–27 (manufacturing and compounding framing)?
Claims 26–27 add process-to-product style language:
- Claim 26: “pharmaceutical composition prepared from a crystalline form of Claim 9 by adding a pharmaceutically acceptable carrier”
- Claim 27: same concept using crystalline form of Claim 12
These do not describe crystallization or manufacturing of the solid form, but they do frame how the drug product composition is made. In litigation, such language can support arguments that a product is made “from” that crystalline form, which is relevant when proving identity of the API form in the finished composition.
How do the PXRD and DSC constraints define infringement risk (what must an accused product prove)?
The patent’s enforceable boundaries are built on analytical markers:
PXRD identity for infringement-critical form
- Claim 1/2/3 lane requires PXRD peaks at:
- 2θ 6.6 ± 0.1
- 2θ 20.2 ± 0.1
- Claim 9/10 lane requires PXRD peaks at:
- 2θ 11.4 ± 0.1
- 2θ 11.6 ± 0.1
An accused crystalline form that does not reproduce those peak locations within those tolerances is positioned to argue non-infringement.
DSC identity as secondary confirmation
- Dependent claims use:
- melting point ~125°C
- DSC onset ~123°C
Even if PXRD matches, failure to match DSC onset or melting point can reduce reliance on dependent claims (but not necessarily Claim 1 or Claim 9 if the dependent features are not required in the independent claim).
What COPD and administration features are required in each claim (indication and dosing route limitations)?
Indication limitation
All “method for treating COPD” claims require COPD treatment in a human.
Route/device limitation
- Nebulizer limitation appears only in dependent claims (Claim 8, 19, 25).
- Therefore, a product administered by other inhalation devices could avoid nebulizer-specific dependent claim coverage while leaving independent and other dependent method claims still in play.
What formulation parameters are protected (isotonicity, pH, citrate buffering, concentration)?
The formulation space protected by dependent claims is not open-ended.
Isotonicity
- Dependent claims: isotonic composition (Claims 4, 15, 21)
pH and buffer identity
- pH about 4–6 (Claims 5, 16, 22)
- citrate buffer to pH about 5 (Claims 6, 17, 23)
This is a clear design constraint: shifting to non-citrate buffering, or outside the pH window, targets the dependent formulation claims.
Concentration window
- about 0.05 μg/mL to about 10 mg/mL (Claims 7, 18, 24)
A product outside that range can potentially avoid those concentration-specific dependents.
How strong is the patent estate for solid form protection under this patent’s claim structure?
Claim strength profile (relative within the patent):
- Highest leverage: dependences to crystalline identity by PXRD.
- Medium leverage: dependences to DSC onset and melting point.
- Medium leverage: formulation-specific dependences (isotonicity, pH, citrate buffer, concentration).
- Lower leverage: nebulizer device limitation, since it can be designed around with alternative delivery while still using the crystalline form.
Design-around implications:
- Switching to a different polymorph or amorphous form that does not have the specified PXRD peak sets is the cleanest theoretical pathway.
- Substituting buffering system or pH outside 4–6, or avoiding citrate buffering at pH ~5, can reduce odds of hitting dependent formulation claims.
- Avoiding nebulizer steps can reduce exposure to nebulizer dependents, but does not remove exposure to claims that do not require that step.
What generic entry risks exist under this patent’s claim scope (crystal-form substitution vs device and formulation changes)?
Risk scenario 1: Same crystalline freebase, different carrier/formulation
- If an abbreviated or generic product uses the same crystalline freebase meeting Claim 1’s PXRD identifiers, a generic that administers for COPD may still face Claim 1 exposure even if it changes isotonicity, citrate buffer, pH, or concentration.
- Carrier identity is “pharmaceutically acceptable,” which is broad.
Risk scenario 2: Same drug substance but different crystal form
- If the generic uses a different crystalline form not matching either PXRD set (6.6/20.2 or 11.4/11.6), the patent’s form-specific claims are harder to assert.
- However, litigation may still attempt to argue that the accused product’s measured PXRD pattern meets the tolerance bands or that it contains the claimed crystalline form as a component.
Risk scenario 3: Same crystal, different buffer/pH, different concentration
- Expected outcome: fewer dependent claim matches (Claims 4–7, 15–19, 21–25).
- Independent method claims remain plausible if they are not limited to those dependents.
Risk scenario 4: Same crystal and formulation, different device
- Avoids nebulizer-specific dependents (Claim 8, 19, 25).
- Independent method claims remain potentially asserted.
What patent landscape questions are answerable from the claim text alone (and which are not)?
Answerable from claim text:
- The patent’s enforceable scope is heavily constrained to specific crystalline forms defined by PXRD peak positions plus optional DSC/melting identifiers.
- The method coverage is for COPD treatment in humans with pharmaceutical compositions containing the claimed crystalline forms.
- Dependent claims create additional constraints around isotonicity, pH, citrate buffer pH ~5, concentration, and nebulizer use.
Not determinable from the provided input:
- Priority dates, filing history, prosecution events, claim construction determinations, expiration/term including patent term adjustment, and whether the patent is listed in FDA Orange Book or tied to specific NDA/BLA numbers.
- Related patents in the same family and their claim differences.
Key takeaways
- US 11,858,898 is a crystalline-form driven patent: infringement is anchored to PXRD peak locations for two distinct solid-state identifiers.
- COPD treatment coverage exists in method claims that require administration of a composition containing the PXRD-defined crystalline freebase/form.
- The most meaningful dependencies for narrowing coverage are DSC/melting identifiers and formulation limits: isotonicity, pH 4–6, citrate buffer to pH ~5, and 0.05 μg/mL to 10 mg/mL concentration window.
- Nebulizer use is limited to dependent claims; avoiding the nebulizer step can reduce, but not eliminate, exposure.
- The primary generic design-around lever is using a different solid form that does not reproduce the claimed PXRD peaks within stated tolerances.
FAQs
-
If a product matches the compound but uses a different polymorph, does US 11,858,898 still apply?
Claim coverage is tied to crystalline identity by specific PXRD peak sets. A different polymorph can avoid those identity-dependent claim elements.
-
Do isotonicity and citrate buffer constraints apply to every claim?
No. They are in dependent claims (Claims 4/15/21 and 6/17/23) tied to the composition used in the method claims.
-
Is nebulizer administration required for infringement of the broadest method claims?
No. Nebulizer appears in dependent claims (Claim 8, 19, 25), not the baseline method claim.
-
Can a product infringe through DSC/melting point even if PXRD differs?
The independent identity rests on PXRD peak locations; DSC/melting appear as additional limitations in dependent claims.
-
Does US 11,858,898 protect how the crystalline form is manufactured?
The provided claim text primarily protects composition made from the claimed crystalline form (Claims 26–27) and not a standalone crystallization process in the excerpts provided.
References
No references are provided in the prompt.
